0.18
-0.009(-4.72%)
Currency In USD
Address
1900 Lake Park Drive
Smyrna, GA 30080
United States of America
Phone
678 384 7220
Website
Sector
Healthcare
Industry
Biotechnology
Employees
17
First IPO Date
September 25, 2020
| Name | Title | Pay | Year Born |
| David Alan Dodd | Chairman, President & Chief Executive Officer | 570,300 | 1950 |
| Mark W. Reynolds | Chief Financial Officer & Corporate Secretary | 348,200 | 1962 |
| Mark J. Newman | Chief Scientific Officer | 422,675 | 1955 |
| Kelly T. McKee Jr. | Chief Medical Officer | 501,104 | 1950 |
| Harriet Latham Robinson | Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board | 0 | 1938 |
| John W. Sharkey | Vice President of Business Development | 0 | 1956 |
| Jeffrey Welch | Head of Process Development & Manufacturing Operations | 0 | N/A |
| Thomas O'Brien | Vice President of Quality Systems & Compliance | 0 | N/A |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.